Related Experiment Video
Updated: Jun 6, 2025
09:29
Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
2.3K
Presumed gabapentin-induced myoclonus in two cats
Caroline Buckley1, Croix Griffin1, Heather Anderson1
1Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, OH, USA.
JFMS Open Reports
|December 2, 2024
Summary
This case report details two cats experiencing gabapentin-induced myoclonus, a condition previously undocumented in felines. The findings suggest potential links between gabapentin use, chronic kidney disease, and neurological events in cats.
Area of Science:
- Veterinary Neurology
- Pharmacology
Background:
- Gabapentin is commonly used in veterinary medicine for managing pain and anxiety.
- Myoclonus, involuntary muscle jerks, is a known side effect in humans but has not been reported in cats.
Observation:
- Two cats with International Renal Interest Society (IRIS) stage 2 chronic kidney disease and seizure history presented with new-onset myoclonus.
- The myoclonus occurred after administration of gabapentin (11.8–16.4 mg/kg) for pre-visit anxiety.
Findings:
- These cases represent the first documented instances of presumed gabapentin-induced myoclonus in cats.
- The observed risk factors, including chronic kidney disease and prior seizures, parallel those reported in human patients.
Implications:
- Veterinarians should consider gabapentin-induced myoclonus in cats, especially those with pre-existing conditions.
- Further research is warranted to explore the role of chronic kidney disease and other neurological factors in feline gabapentin toxicity.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
144
01:14Antiepileptic Drugs: Glutamate Antagonists
281
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
281
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
328
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
328
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
248
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:15Myasthenia Gravis: Diagnostic Tests
644
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
644